These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15553667)

  • 1. [Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].
    Tsuruma T; Torigoe T; Hata F; Furuhata T; Sato N; Hirata K
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1634-6. PubMed ID: 15553667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
    Tsuruma T; Hata F; Torigoe T; Furuhata T; Idenoue S; Kurotaki T; Yamamoto M; Yagihashi A; Ohmura T; Yamaguchi K; Katsuramaki T; Yasoshima T; Sasaki K; Mizushima Y; Minamida H; Kimura H; Akiyama M; Hirohashi Y; Asanuma H; Tamura Y; Shimozawa K; Sato N; Hirata K
    J Transl Med; 2004 Jun; 2(1):19. PubMed ID: 15193151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
    Honma I; Kitamura H; Torigoe T; Takahashi A; Tanaka T; Sato E; Hirohashi Y; Masumori N; Tsukamoto T; Sato N
    Cancer Immunol Immunother; 2009 Nov; 58(11):1801-7. PubMed ID: 19294381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
    Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
    J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
    Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
    Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
    Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
    Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
    Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
    Ichiki Y; Hanagiri T; Takenoyama M; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Sugaya M; Yasuda M; So T; Sugio K; Yasumoto K
    Lung Cancer; 2005 May; 48(2):281-9. PubMed ID: 15829330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
    Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
    Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.
    Karanikas V; Soukou F; Kalala F; Kerenidi T; Grammoustianou ES; Gourgoulianis KI; Germenis AE
    Clin Immunol; 2008 Nov; 129(2):230-40. PubMed ID: 18789878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer.
    Andersen MH; Soerensen RB; Becker JC; thor Straten P
    J Transl Med; 2006 Sep; 4():38. PubMed ID: 16948867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
    Kubo T; Tsurita G; Hirohashi Y; Yasui H; Ota Y; Watanabe K; Murai A; Matsuo K; Asanuma H; Shima H; Wada S; Nakatsugawa M; Kanaseki T; Tsukahara T; Mizuguchi T; Hirata K; Takemasa I; Imai K; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2386-2395. PubMed ID: 31206934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-B35-restricted immune responses against survivin in cancer patients.
    Reker S; Becker JC; Svane IM; Ralfkiaer E; Straten PT; Andersen MH
    Int J Cancer; 2004 Mar; 108(6):937-41. PubMed ID: 14712500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin.
    Otto K; Andersen MH; Eggert A; Keikavoussi P; Pedersen LØ; Rath JC; Böck M; Bröcker EB; Straten PT; Kämpgen E; Becker JC
    Vaccine; 2005 Jan; 23(7):884-9. PubMed ID: 15603888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
    Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin--a universal tumor antigen.
    Andersen MH; thor SP
    Histol Histopathol; 2002 Apr; 17(2):669-75. PubMed ID: 11962766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.